Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders
The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.
CTN Protocol ID:
CTN-0028
DSMB ID:
DSMB-0028
Enrollment Status:
Completed
ClinicalTrials.gov ID:
Primary Outcomes Article:
Riggs, P., et al. (2011). Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. Journal of the American Academy of Child & Adolescent Psychiatry 50(9):903-14.
http://www.ncbi.nlm.nih.gov/pubmed/21871372
Featured Publication
Drugs, Brains, and Behavior - The Science of Addiction
As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.
